Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003895 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
A Phase 2 study of Recurrent Melanoma and Stage IIIC Melanoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00003895 is a Phase 2 study of Recurrent Melanoma and Stage IIIC Melanoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants, below the 171-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00003895, a Phase 2 study of Recurrent Melanoma and Stage IIIC Melanoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized pilot phase II trial studies how well vaccine therapy works in treating human leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL HPV 16 E7:12-20
- BIOLOGICAL gp100:209-217(210M)
Study Locations (1)
Oregon
- Providence Portland Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1999-04 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003895
The ClinicalTrials.gov registry entry for NCT00003895 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 171-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (79% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00003895 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT00003895 about?
NCT00003895 is a clinical study titled "Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma". This randomized pilot phase II trial studies how well vaccine therapy works in treating human leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.
What is the current status of trial NCT00003895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 1999-04. Estimated completion is 2013-09.
What conditions does trial NCT00003895 study?
This clinical trial studies the following conditions: Recurrent Melanoma, Stage IIIC Melanoma, Stage IA Melanoma, Stage IB Melanoma, Stage IIA Melanoma.
What interventions are being tested in trial NCT00003895?
The interventions under investigation include: laboratory biomarker analysis (OTHER), HPV 16 E7:12-20 (BIOLOGICAL), gp100:209-217(210M) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003895?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003895 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dinaciclib in Treating Patients With Stage IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
COMPLETED · Phase 2
-
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.